ES2158048T3 - Mutaciones del gen ligado al cromosoma 17q, de susceptibilidad al cancer de mama y de ovario. - Google Patents

Mutaciones del gen ligado al cromosoma 17q, de susceptibilidad al cancer de mama y de ovario.

Info

Publication number
ES2158048T3
ES2158048T3 ES95305605T ES95305605T ES2158048T3 ES 2158048 T3 ES2158048 T3 ES 2158048T3 ES 95305605 T ES95305605 T ES 95305605T ES 95305605 T ES95305605 T ES 95305605T ES 2158048 T3 ES2158048 T3 ES 2158048T3
Authority
ES
Spain
Prior art keywords
breast
ovarian cancer
cancer
mutations
susceptibility
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
ES95305605T
Other languages
English (en)
Other versions
ES2158048T5 (es
Inventor
Donna M Shattuck-Eidens
Jacques Simard
Mitsuru Emi
Yusuke Nakamura
Francine Durocher
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Centre de Recherche du CHUL
Cancer Institute
Myriad Genetics Inc
Original Assignee
Centre de Recherche du CHUL
Cancer Institute
Myriad Genetics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=27569596&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=ES2158048(T3) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Priority claimed from US08/480,784 external-priority patent/US5693473A/en
Priority claimed from US08/483,553 external-priority patent/US5709999A/en
Application filed by Centre de Recherche du CHUL, Cancer Institute, Myriad Genetics Inc filed Critical Centre de Recherche du CHUL
Publication of ES2158048T3 publication Critical patent/ES2158048T3/es
Application granted granted Critical
Publication of ES2158048T5 publication Critical patent/ES2158048T5/es
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/1703—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • A61K38/1709—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4702—Regulators; Modulating activity
    • C07K14/4703—Inhibitors; Suppressors
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/82—Translation products from oncogenes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • C12Q1/6886—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2217/00—Genetically modified animals
    • A01K2217/05—Animals comprising random inserted nucleic acids (transgenic)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/136—Screening for pharmacological compounds
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/172—Haplotypes

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Zoology (AREA)
  • Genetics & Genomics (AREA)
  • General Health & Medical Sciences (AREA)
  • Biochemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Medicinal Chemistry (AREA)
  • Immunology (AREA)
  • Molecular Biology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biophysics (AREA)
  • Wood Science & Technology (AREA)
  • Oncology (AREA)
  • Analytical Chemistry (AREA)
  • Pathology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Microbiology (AREA)
  • Marine Sciences & Fisheries (AREA)
  • Animal Behavior & Ethology (AREA)
  • Hospice & Palliative Care (AREA)
  • Public Health (AREA)
  • Toxicology (AREA)
  • Physics & Mathematics (AREA)
  • Biotechnology (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Engineering & Computer Science (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)

Abstract

LA PRESENTE INVENCION SE REFIERE GENERALMENTE AL CAMPO DE LA GENETICA HUMANA. ESPECIFICAMENTE LA PRESENTE INVENCION SE REFIERE A METODOS Y MATERIALES UTILIZADOS PARA AISLAR Y DETECTAR UN GEN HUMANO DE PREDISPOSICION AL CANCER DE OVARIOS Y MAMA (BRCA1), ALGUNOS ALELOS MUTANTES QUE CAUSAN LA SUSCEPTIBILIDAD AL CANCER, EN PARTICULAR CANCER DE MAMA Y OVARIOS. MAS ESPECIFICAMENTE, LA INVENCION SE REFIERE A MUTACIONES DE LA LINEA GERMINAL EN EL GEN BRCA1 Y SU USO EN LA DIAGNOSIS DE LA PREDISPOSICION AL CANCER DE OVARIOS Y MAMA. LA PRESENTE INVENCION SE REFIERE ADEMAS A MUTACIONES SOMATICAS EN EL GEN BRCA1 EN EL CANCER DE OVARIOS Y DE MAMA HUMANO Y SU USO EN LA DIAGNOSIS Y PROGNOSIS DE DICHO CANCER.
ES95305605T 1994-08-12 1995-08-11 Mutaciones del gen ligado al cromosoma 17q, de susceptibilidad al cancer de mama y de ovario. Expired - Lifetime ES2158048T5 (es)

Applications Claiming Priority (14)

Application Number Priority Date Filing Date Title
US28922194A 1994-08-12 1994-08-12
US30026694A 1994-09-02 1994-09-02
US300266 1994-09-02
US30810494A 1994-09-16 1994-09-16
US308104 1994-09-16
US34882494A 1994-11-29 1994-11-29
US348824 1994-11-29
US40930595A 1995-03-24 1995-03-24
US409305 1995-03-24
US483553 1995-06-07
US480784 1995-06-07
US08/480,784 US5693473A (en) 1994-08-12 1995-06-07 Linked breast and ovarian cancer susceptibility gene
US08/483,553 US5709999A (en) 1994-08-12 1995-06-07 Linked breast and ovarian cancer susceptibility gene
US289221 1999-04-09

Publications (2)

Publication Number Publication Date
ES2158048T3 true ES2158048T3 (es) 2001-09-01
ES2158048T5 ES2158048T5 (es) 2009-11-04

Family

ID=27569596

Family Applications (1)

Application Number Title Priority Date Filing Date
ES95305605T Expired - Lifetime ES2158048T5 (es) 1994-08-12 1995-08-11 Mutaciones del gen ligado al cromosoma 17q, de susceptibilidad al cancer de mama y de ovario.

Country Status (16)

Country Link
EP (1) EP0705903B2 (es)
JP (1) JP2002503943A (es)
CN (1) CN1172502A (es)
AT (1) ATE201445T1 (es)
AU (1) AU686004B2 (es)
CA (1) CA2196797C (es)
DE (1) DE69521002T3 (es)
DK (1) DK0705903T3 (es)
ES (1) ES2158048T5 (es)
FI (1) FI970513A (es)
GR (1) GR3036322T3 (es)
MX (1) MX9701075A (es)
NO (1) NO970624L (es)
NZ (1) NZ291621A (es)
PT (1) PT705903E (es)
WO (1) WO1996005306A2 (es)

Families Citing this family (62)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1995019369A1 (en) 1994-01-14 1995-07-20 Vanderbilt University Method for detection and treatment of breast cancer
EP0804453A4 (en) * 1995-01-17 2004-08-11 Univ Vanderbilt METHOD FOR DETECTING AND TREATING BREAST CANCER
US5654155A (en) * 1996-02-12 1997-08-05 Oncormed, Inc. Consensus sequence of the human BRCA1 gene
US6951721B2 (en) 1996-02-12 2005-10-04 Gene Logic Inc. Method for determining the haplotype of a human BRCA1 gene
US6838256B2 (en) * 1996-02-12 2005-01-04 Gene Logic Inc. Coding sequences of the human BRCA1 gene
US5891857A (en) * 1996-02-20 1999-04-06 Vanderbilt University Characterized BRCA1 and BRCA2 proteins and screening and therapeutic methods based on characterized BRCA1 and BRCA2 proteins
AU4586697A (en) * 1996-09-20 1998-04-14 Board Of Regents, The University Of Texas System Compositions and methods comprising bard1 and other brca1 binding proteins
WO1998031801A1 (en) 1997-01-21 1998-07-23 Human Genome Sciences, Inc. I-flice, a novel inhibitor of tumor necrosis factor receptor-1 and cd-95 induced apoptosis
US5965377A (en) * 1997-03-24 1999-10-12 Baystate Medical Center Method for determining the presence of mutated BRCA protein
US6733966B1 (en) 1997-06-04 2004-05-11 Rijksuniversiteit Te Leiden Diagnostic test kit for determining a predisposition for breast and ovarian cancer, materials and methods for such determination
US6492109B1 (en) 1997-09-23 2002-12-10 Gene Logic, Inc. Susceptibility mutation 6495delGC of BRCA2
WO1999024614A1 (en) 1997-11-06 1999-05-20 Oklahoma Medical Research Foundation Diagnostic assay for cancer susceptibility
US6177410B1 (en) 1997-12-05 2001-01-23 Vanderbilt University Therapeutic methods for prostate cancer
US6686163B2 (en) 1998-05-06 2004-02-03 Gene Logic Inc. Coding sequence haplotype of the human BRCA1 gene
US7151102B2 (en) 2000-10-30 2006-12-19 Kudos Pharmaceuticals Limited Phthalazinone derivatives
CA2482806A1 (en) 2002-04-30 2003-11-13 Kudos Pharmaceuticals Limited Phthalazinone derivatives
GB0210121D0 (en) 2002-05-02 2002-06-12 Celltech R&D Ltd Biological products
DK1507556T3 (en) 2002-05-02 2016-09-12 Wyeth Holdings Llc Calicheamicin derivative-carrier conjugates
GB0305681D0 (en) 2003-03-12 2003-04-16 Kudos Pharm Ltd Phthalazinone derivatives
US7449464B2 (en) 2003-03-12 2008-11-11 Kudos Pharmaceuticals Limited Phthalazinone derivatives
ES2545613T3 (es) 2003-12-01 2015-09-14 Kudos Pharmaceuticals Limited Inhibidores de reparación de daño en el ADN para el tratamiento del cáncer
GB0419072D0 (en) 2004-08-26 2004-09-29 Kudos Pharm Ltd Phthalazinone derivatives
KR101138862B1 (ko) 2005-02-14 2012-05-14 삼성전자주식회사 단일염기 다형을 포함하는 유방암과 관련된 폴리뉴클레오티드, 그를 포함하는 마이크로어레이 및 진단 키트 및 그를이용한 유방암 진단 방법
KR101206028B1 (ko) 2005-03-05 2012-11-28 삼성전자주식회사 유방암 특이적 다형성 서열을 이용한 유방암의 진단방법,유방암 특이적인 폴리뉴클레오티드 및 상기 폴리뉴클레오티드가 고정되어 있는 마이크로어레이
GB0521373D0 (en) 2005-10-20 2005-11-30 Kudos Pharm Ltd Pthalazinone derivatives
US8768629B2 (en) 2009-02-11 2014-07-01 Caris Mpi, Inc. Molecular profiling of tumors
IL301804A (en) 2006-05-18 2023-05-01 Caris Mpi Inc A system and method for determining a personalized medical intervention for a disease stage
WO2007138355A1 (en) 2006-05-31 2007-12-06 Istituto Di Ricerche Di Biologia Molecolare P. Angeletti Spa Pyrrolo[1,2-a]pyrazin-1(2h)-one and pyrrolo[1,2-d][1,2,4]triazin-1(2h)-one derivatives as inhibitors of poly(adp-ribose)polymerase(parp)
UY30639A1 (es) 2006-10-17 2008-05-31 Kudos Pharm Ltd Derivados sustituidos de 2h-ftalazin-1-ona, sus formas cristalinas, proceso de preparacion y aplicaciones
EP2109608B1 (en) 2007-01-10 2011-03-23 Istituto di Richerche di Biologia Molecolare P. Angeletti S.p.A. Amide substituted indazoles as poly(adp-ribose)polymerase (parp) inhibitors
EP2188278A1 (en) 2007-09-14 2010-05-26 AstraZeneca AB Phthalazinone derivatives
MX2010004028A (es) 2007-10-17 2010-04-30 Kudos Pharm Ltd 4-[3-(4-ciclopropancarbonil-piperacin-1-carbonil)-4-fluoro-bencil ]-2h-ftalacin-1-ona.
AR070221A1 (es) 2008-01-23 2010-03-25 Astrazeneca Ab Derivados de ftalazinona inhibidores de polimerasas, composiciones farmaceuticas que los contienen y usos de los mismos para prevenir y/o tratar tumores cancerigenos,lesiones isquemicas y otras enfermedades asociadas.
ES2466565T3 (es) 2008-08-06 2014-06-10 Biomarin Pharmaceutical Inc. Inhibidores dihidropiridoftalazinona de poli(ADP-ribosa)polimerasa (PARP)
HUE030800T2 (en) 2008-10-07 2017-05-29 Astrazeneca Uk Ltd Pharmaceutical Form No. 514
JP2012508577A (ja) 2008-11-12 2012-04-12 カリス ライフ サイエンシズ ルクセンブルク ホールディングス 表現型を決定するためのエキソソームの使用方法およびそのシステム
UY32790A (es) 2009-07-15 2011-02-28 Astrazeneca Ab Compuesto de ftalazinona
CN103237901B (zh) 2010-03-01 2016-08-03 卡里斯生命科学瑞士控股有限责任公司 用于治疗诊断的生物标志物
KR20130043104A (ko) 2010-04-06 2013-04-29 카리스 라이프 사이언스 룩셈부르크 홀딩스 질병용 순환 생물학적 지표들
CN104789664A (zh) * 2015-04-02 2015-07-22 安诺优达基因科技(北京)有限公司 用于乳腺癌易感基因BRCA1和BRCA2的Long-range PCR检测的引物组、方法及试剂盒
JP6786066B2 (ja) 2016-10-07 2020-11-18 富士通株式会社 家系図作成支援プログラム、家系図作成支援方法、及び家系図作成支援装置
CN109897852A (zh) * 2018-07-25 2019-06-18 广州普世利华科技有限公司 基于C2c2的肿瘤相关突变基因的gRNA、检测方法、检测试剂盒
CN113811333B (zh) 2019-05-14 2024-03-12 诺维逊生物股份有限公司 靶向抗癌核激素受体的化合物
US11325906B2 (en) 2019-07-19 2022-05-10 Astrazeneca Ab Chemical compounds
US11952349B2 (en) 2019-11-13 2024-04-09 Nuvation Bio Inc. Anti-cancer nuclear hormone receptor-targeting compounds
CN113388680B (zh) * 2020-03-14 2023-07-04 复旦大学附属妇产科医院 上皮性卵巢癌靶点ret及其在诊断和治疗中的作用
US11795158B2 (en) 2020-06-25 2023-10-24 Astrazeneca Ab Chemical compounds
WO2022074617A1 (en) 2020-10-09 2022-04-14 Astrazeneca Uk Limited Combination of antibody-drug conjugate and parp1 selective inhibitor
IL306010A (en) 2021-03-23 2023-11-01 Nuvation Bio Inc Anticancer compounds against the nuclear hormone receptor
US12006314B2 (en) 2021-05-03 2024-06-11 Nuvation Bio Inc. Anti-cancer nuclear hormone receptor-targeting compounds
WO2022271547A1 (en) 2021-06-21 2022-12-29 Tesaro, Inc. Combination treatment of cancer with a parp inhibitor and a lipophilic statin
AU2022392822A1 (en) 2021-11-18 2024-05-02 Astrazeneca Uk Limited Combination of antibody-drug conjugate and parp1 selective inhibitor
WO2023118085A1 (en) 2021-12-21 2023-06-29 Astrazeneca Ab Methods of treating brain tumours and neuroblastomas
TW202339805A (zh) 2021-12-28 2023-10-16 英商阿斯特捷利康英國股份有限公司 抗體-藥物結合物及atr抑制劑之組合
TW202333800A (zh) 2021-12-28 2023-09-01 英商阿斯特捷利康英國股份有限公司 抗體-藥物結合物及rasg12c抑制劑之組合
WO2023175483A1 (en) 2022-03-16 2023-09-21 Astrazeneca Uk Limited A scoring method for an anti-trop2 antibody‑drug conjugate therapy
WO2023194528A1 (en) 2022-04-07 2023-10-12 Astrazeneca Ab Combination therapy for treating cancer
WO2023194525A1 (en) 2022-04-07 2023-10-12 Astrazeneca Ab Combination therapy for treating cancer
WO2023194530A1 (en) 2022-04-07 2023-10-12 Astrazeneca Ab Combination therapy for treating cancer
WO2023242302A1 (en) 2022-06-15 2023-12-21 Astrazeneca Ab Combination therapy for treating cancer
TW202412859A (zh) 2022-07-28 2024-04-01 英商阿斯特捷利康英國股份有限公司 抗體-藥物結合物及雙特異性檢查點抑制劑之組合
WO2024116094A1 (en) 2022-11-30 2024-06-06 Daiichi Sankyo Company, Limited Combination of antibody-drug conjugates and dnmt inhibitors

Family Cites Families (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NL154598B (nl) 1970-11-10 1977-09-15 Organon Nv Werkwijze voor het aantonen en bepalen van laagmoleculire verbindingen en van eiwitten die deze verbindingen specifiek kunnen binden, alsmede testverpakking.
US3817837A (en) 1971-05-14 1974-06-18 Syva Corp Enzyme amplification assay
US3939350A (en) 1974-04-29 1976-02-17 Board Of Trustees Of The Leland Stanford Junior University Fluorescent immunoassay employing total reflection for activation
US3996345A (en) 1974-08-12 1976-12-07 Syva Company Fluorescence quenching with immunological pairs in immunoassays
US4277437A (en) 1978-04-05 1981-07-07 Syva Company Kit for carrying out chemically induced fluorescence immunoassay
US4275149A (en) 1978-11-24 1981-06-23 Syva Company Macromolecular environment control in specific receptor assays
US4486530A (en) 1980-08-04 1984-12-04 Hybritech Incorporated Immunometric assays using monoclonal antibodies
US4376110A (en) 1980-08-04 1983-03-08 Hybritech, Incorporated Immunometric assays using monoclonal antibodies
US4366241A (en) 1980-08-07 1982-12-28 Syva Company Concentrating zone method in heterogeneous immunoassays
CA1188246A (en) 1981-08-31 1985-06-04 Jerry L. Gregory Immobilized microbe recycle apparatus
NZ207394A (en) 1983-03-08 1987-03-06 Commw Serum Lab Commission Detecting or determining sequence of amino acids
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
US4683202A (en) 1985-03-28 1987-07-28 Cetus Corporation Process for amplifying nucleic acid sequences
US4683195A (en) 1986-01-30 1987-07-28 Cetus Corporation Process for amplifying, detecting, and/or-cloning nucleic acid sequences
US4868105A (en) 1985-12-11 1989-09-19 Chiron Corporation Solution phase nucleic acid sandwich assay
IE61148B1 (en) 1988-03-10 1994-10-05 Ici Plc Method of detecting nucleotide sequences
ES2264239T3 (es) * 1990-06-27 2006-12-16 Princeton University Complejo de proteinas p53/p90'.
IL103059A0 (en) 1991-09-30 1993-02-21 Boehringer Ingelheim Int Conjugates for introducing nucleic acid into higher eucaryotic cells
US5252479A (en) 1991-11-08 1993-10-12 Research Corporation Technologies, Inc. Safe vector for gene therapy
WO1994000764A1 (en) * 1992-06-26 1994-01-06 THE UNITED STATES OF AMERICA, represented by THE SECRETARY OF HEALTH AND HUMAN SERVICES The met proto-oncogene and a method for predicting breast cancer progression
WO1995019369A1 (en) * 1994-01-14 1995-07-20 Vanderbilt University Method for detection and treatment of breast cancer
EP0804453A4 (en) * 1995-01-17 2004-08-11 Univ Vanderbilt METHOD FOR DETECTING AND TREATING BREAST CANCER

Also Published As

Publication number Publication date
DK0705903T3 (da) 2001-08-27
EP0705903B2 (en) 2009-08-12
CA2196797A1 (en) 1996-02-22
NZ291621A (en) 1998-09-24
DE69521002D1 (de) 2001-06-28
CA2196797C (en) 2000-10-10
WO1996005306A2 (en) 1996-02-22
DE69521002T2 (de) 2001-11-15
NO970624L (no) 1997-04-14
NO970624D0 (no) 1997-02-11
FI970513A (fi) 1997-04-07
GR3036322T3 (en) 2001-11-30
AU3321295A (en) 1996-03-07
MX9701075A (es) 1998-03-31
PT705903E (pt) 2001-11-30
ES2158048T5 (es) 2009-11-04
DE69521002T3 (de) 2010-02-25
CN1172502A (zh) 1998-02-04
WO1996005306A3 (en) 1996-03-14
ATE201445T1 (de) 2001-06-15
JP2002503943A (ja) 2002-02-05
EP0705903B1 (en) 2001-05-23
EP0705903A1 (en) 1996-04-10
AU686004B2 (en) 1998-01-29
FI970513A0 (fi) 1997-02-07

Similar Documents

Publication Publication Date Title
ES2158048T3 (es) Mutaciones del gen ligado al cromosoma 17q, de susceptibilidad al cancer de mama y de ovario.
ES2164136T3 (es) Gen de susceptibilidad al cancer de mama y de ovarios asociado a 17q.
NO982785D0 (no) Kromosom 13-koblet brystkreftmottagelighetsgen
EP1260520A3 (en) Chromosome 13-linked breast cancer susceptibility gene
CA2300355A1 (en) Detection of genetic alterations of chromosome 20q that are associated with breast cancer
DE60135022D1 (de) Antitumoraktivität zeigendes runx3-gen und dessen verwendung
WO1998025125A3 (en) Predisposition to breast cancer by mutations at the ataxia-telangiectasia genetic locus
MX9701074A (es) Gen de susceptibilidad al cancer de pecho y ovario enlazado con 17q.
ATE346150T1 (de) Isolierte sh3 gene, die mit myeloproliferativen erkrankungen und leukämie verbunden sind, und deren verwendungen

Legal Events

Date Code Title Description
FG2A Definitive protection

Ref document number: 705903

Country of ref document: ES